Helus Pharma Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cybin Inc. (CYBN) is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics, including proprietary deuterated tryptamine derivatives, for the treatment of mental health conditions such as major depressive disorder (MDD) and generalized anxiety disorder (GAD). The company engineers novel molecules with controllable drug delivery systems through its deuterated process, offering CYB003, a deuterated psilocin analog in Phase 3 development as an adjunctive oral treatment for MDD with FDA Breakthrough Therapy Designation; CYB004, a deuterated N,N-dimethyltryptamine (dDMT) molecule administered intramuscularly in Phase 2 for GAD; CYB005 targeting central nervous system disorders via phenethylamines and tryptamines; and an early-stage research pipeline of investigational 5-HT receptor-focused compounds, supported by over 100 granted patents and more than 250 pending applications. Founded in 2019 and headquartered at 5600-100 King Street West, Suite 5600, Toronto, Ontario, Canada, Cybin operates primarily in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. Recent developments include the completion of enrollment in the Phase 2 CYB004 study for GAD and positive Phase 2 data for CYB003 demonstrating 12-month efficacy in MDD; dosing underway in the Phase 3 PARADIGM program for CYB003 with plans to initiate the second pivotal EMBRACE study in Q4 2025; a US$175 million registered direct offering closed in October 2025 strengthening its cash position to US$83.8 million as of September 30, 2025; a strategic manufacturing partnership with Thermo Fisher Scientific in 2025 for Phase 3 clinical supply and potential commercialization of CYB003; and a prior up-to-US$500 million financing agreement with High Trail Special Situations LLC announced in mid-2025.
Company News
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout
Helus Pharma to Host Investor Presentation on October 21, 2026
Helus Pharma Announces Completion of Legal Name Change
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
Insider Buying: Cybin (NASDAQ:HELP) Insider Purchases $1,239,000.00 in Stock
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board